BERWYN, Pennsylvanie–(BUSINESS WIRE)–Nordic Pharma, Inc., une filiale de Nordic Group B.V., a lancé le gel canaliculaire LACRIFILL, un nouveau traitement pour la sécheresse oculaire aux États-Unis. Le gel canaliculaire LACRIFILL est un dérivé réticul…
Author: Business Wire
Samenvatting: Nordic Group B.V. kondigt via haar dochteronderneming Nordic Pharma, Inc. (VS) de lancering aan van LACRIFILL® Canalicular Gel, een nieuwe therapie voor droge ogen.
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., een dochteronderneming van Nordic Group B.V., heeft LACRIFILL Canalicular Gel gelanceerd, een nieuwe therapie voor droge ogen in de VS. LACRIFILL Canalicular Gel is een verknoopt hyaluronzuurderivaat e…
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc. has launched LACRIFILL® Canalicular Gel, a novel therapy for dry eye in the U.S.
Riassunto: Nordic Group B.V. attraverso la sua affiliata Nordic Pharma, Inc. (U.S.), annuncia il lancio del gel canalicolare LACRIFILL®, un’innovativa terapia per la sindrome dell’occhio secco.
BERWYN, Pennsylvania–(BUSINESS WIRE)–Nordic Pharma, Inc., un’affiliata di Nordic Group B.V., ha lanciato il gel canalicolare LACRIFILL, un’innovativa terapia per la sindrome dell’occhio secco, negli Stati Uniti; di derivazione dall’acido ialuronico, …
LambdaVision Announces First Closing of Seed Round to Advance Artificial Retina Preclinical Studies for Retinal Eye Diseases
FARMINGTON, Conn.–(BUSINESS WIRE)–LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round b…
National Vision Holdings, Inc. to Participate in Upcoming Investor Conferences
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced the Company’s participation in the following upcoming investor conferences: Jefferies Healthcare Conference. The Company is scheduled to participate in a firesid…
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Bra…
Merck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have en…
Global Nonmydriatic Handheld Fundus Cameras Strategic Research Report 2024: Rise in Prevalence of Eye Disorders Present Favorable Outlook – Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Nonmydriatic Handheld Fundus Cameras – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. Global Nonmydriatic Handheld Fundus Cameras Market to Reach $259 Million by 2030 The global mark…
Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Ass…
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
BERLIN–(BUSINESS WIRE)–Dopavision, a pioneering company dedicated to transforming pediatric eye care, today announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). The six-month outcomes of the randomized, control…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual ra…
Exonate Appoints Dr Rafiq Hasan as Non-Executive Director
CAMBRIDGE, England–(BUSINESS WIRE)–Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Ra…
iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data
NEW YORK–(BUSINESS WIRE)– #AI–iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk o…
LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executi…
Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category
BRIDGEWATER, N.J.–(BUSINESS WIRE)–RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best f…
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients
GUILFORD, Conn. & SHANGHAI–(BUSINESS WIRE)–Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (AL…
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24th Ann…
Ophthalmic Devices, Diagnostics and Surgical Equipment Global Markets Report 2023-2024 and 2028: Trends and Technologies, Patent and Pipeline Analysis, Outlook, Competitive Landscape, ESG Developments – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Devices, Diagnostics and Surgical Equipment: Global Markets 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The Global Ophthalmic Devices, Diagnostics and Surgical Equipment Market was val…